by Clinical Neuropsychologist | Wednesday, April 17, 2024 | Dementia
Abstract INTRODUCTION Cerebral small vessel disease (SVD) is a common cause of stroke/vascular dementia with few effective treatments. Neuroinflammation and increased blood-brain barrier (BBB) permeability may influence pathogenesis. In rodent models, minocycline...
by Clinical Neuropsychologist | Wednesday, April 17, 2024 | Dementia
Abstract INTRODUCTION Age-related magnetic resonance imaging (MRI) T2 white matter hyperintensities (WMHs) are common and associated with neurological decline. We investigated the histopathological underpinnings of MRI WMH and surrounding normal appearing white matter...
by Clinical Neuropsychologist | Wednesday, April 17, 2024 | Dementia
Abstract INTRODUCTION In trials of amyloid-lowering drugs for Alzheimer’s disease (AD), differential eligibility may contribute to under-inclusion of racial and ethnic underrepresented groups. We examined plasma amyloid beta 42/40 and positron emission...
by Clinical Neuropsychologist | Tuesday, April 16, 2024 | Dementia
Abstract INTRODUCTION Ozone (O3) is an air pollutant associated with Alzheimer’s disease (AD) risk. The lung–brain axis is implicated in O3-associated glial and amyloid pathobiology; however, the role of disease-associated astrocytes (DAAs) in this process...
by Clinical Neuropsychologist | Tuesday, April 16, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) is characterized by cognitive impairments; however, heightened anxiety often accompanies and, in some cases, exacerbates cognitive its. The present study aims to understand the influence of multiple variables on...
by Clinical Neuropsychologist | Tuesday, April 16, 2024 | Dementia
Abstract INTRODUCTION Effective longitudinal biomarkers that track disease progression are needed to characterize the presymptomatic phase of genetic frontotemporal dementia (FTD). We investigate the utility of cerebral perfusion as one such biomarker in...
